Beam Therapeutics(BEAM.US) Officer Sells US$1.47 Million in Common Stock

$Beam Therapeutics(BEAM.US)$ Officer Evans John M. sold 60,000 shares of common stock on Jun 27, 2024 at an average price of $24.5026 for a total value of $1.47 million.Source: Announcement What is st

Futu NewsJun 29 04:56

Beam Therapeutics Insider Sold Shares Worth $1,470,156, According to a Recent SEC Filing

John M. Evans, Director, CEO, on June 27, 2024, sold 60,000 shares in Beam Therapeutics (BEAM) for $1,470,156. Following the Form 4 filing with the SEC, Evans has control over a total of 1,101,343 sha

MT NewswiresJun 29 04:30

Form 144 | Beam Therapeutics(BEAM.US) Officer Proposes to Sell 1.47 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 27, $Beam Therapeutics(BEAM.US)$ Officer JOHN M EVANS intends to sell 60,000 shares of its common stock on Jun 27, with a total market value of approximately $1.47 million.

Futu NewsJun 28 04:19

Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating

Wells Fargo analyst Yanan Zhu maintains $Beam Therapeutics(BEAM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.9% and a total average return of 12.6% over the

Futu NewsJun 27 09:31 · Ratings

Beam Therapeutics Announced The First Patient Was Treated With BEAM-302, An Investigational In Vivo Base Editing Medicine Designed To Precisely Correct The Underlying Cause Of Severe Alpha-1 Antitrypsin Deficiency, Currently In Phase 1/2 Trial

Beam Therapeutics Announced The First Patient Was Treated With BEAM-302, An Investigational In Vivo Base Editing Medicine Designed To Precisely Correct The Underlying Cause Of Severe Alpha-1 Antitryps

BenzingaJun 26 18:34

Express News | Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd)

BreakingsJun 26 18:30